Previous 10 | Next 10 |
Karyopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future Oncology - Treatment with Selinexor Demonstrated Several Potential Clinical Advantages Compared to Pla...
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) traded at a new 52-week low today of $9.73. So far today approximately 720,000 shares have been exchanged, as compared to an average 30-day volume of 2 million shares. Karyopharm Therapeutics Inc. has overhead space with shares priced $9.81, or ...
Gainers: [[GLYC]] +3.5%. [[CBAY]] +2.6%. [[KPTI]] +2.6%. [[GMAB]] +2.5%. [[SYRS]] +2.4%.Losers: [[VECT]] -8.1%. [[TCRR]] -2.4%. [[JFIN]] -2.3%. [[CENX]] -2.2%. [[GURE]] -1.8%. For further details see: KPTI, CENX, GMAB and TCRR among after-hours movers
Karyopharm Therapeutics ([[KPTI]] -0.6%) announces that the European Commission ((EC)) has granted conditional marketing authorization for NEXPOVIO (selinexor) in combination with dexamethasone for the treatment of multiple myeloma in certain patients.The approval allows for the use of the co...
Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma -- NEXPOVIO is the First and Only Nuclear Ex...
KPTI has fallen 30% on earnings. COVID-19 and some increasing competition have caused lackluster growth. However, the pipeline potential does not justify a sub-$1 billion valuation. For further details see: Karyopharm Stock: Rationale For Bullishness
Karyopharm Announces Upcoming Virtual Investor Conference Participation PR Newswire NEWTON, Mass. , Feb. 17, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today a...
Karyopharm Therapeutics Inc. (KPTI) Q4 2020 Earnings Conference Call February 11, 2021 8:30 AM ET Company Participants Ian Karp - Senior Vice President, Investor and Public Relations Michael Kauffman - Chief Executive Officer Michael Mason - Chief Financial Officer John Demaree - Chief Commer...
Image source: The Motley Fool. Karyopharm Therapeutics Inc (NASDAQ: KPTI) Q4 2020 Earnings Call Feb 11, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics Inc (KPTI) Q4 2020 Earnings Call Transc...
The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Karyopharm Therapeutics Inc. 2020 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...
Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...